DEA revokes Texas pharmacy registration over prescriptions outside professional practice

The Drug Enforcement Administration has revoked the controlled-substance registration of Arenbii Pharmacy LLC, a pharmacy based in Missouri City, Texas, and denied its pending applications, in a default final order published in the Federal Register on October 7, 2026. The order, signed by DEA Administrator Terrance C. Cole, cancels Certificate of Registration No. FA3529849 and takes effect November 6, 2026.

The decision closes a case opened on September 17, 2025, when DEA issued an Order to Show Cause and Immediate Suspension of Registration to the pharmacy, alleging that its continued registration constituted an imminent danger to public health or safety under 21 U.S.C. 824(d). The Government filed a Request for Final Agency Action on February 5, 2026, seeking a default final order. Because the registrant neither requested a hearing nor answered the allegations, it was deemed in default under 21 CFR 1301.43 and is treated as having admitted the facts charged.

A default built on admitted facts

DEA found that the pharmacy repeatedly filled controlled-substance prescriptions containing multiple red flags of abuse or diversion without addressing or resolving them, from at least January 10, 2024, through at least May 12, 2025. The agency said the conduct violated federal law and Texas pharmacy rules, which require a pharmacist to resolve red flags before dispensing.

The order also denies any pending application by Arenbii Pharmacy LLC to renew or modify the registration, as well as any other pending application for additional registration in Texas.

Pattern prescribing and opioid volumes

DEA found that between April 20, 2022, and May 12, 2025, more than 90 percent of the Schedule II opioid prescriptions the pharmacy filled were written by a single physician, Dr. M.Q., for similar strengths and quantities. The agency identified at least 67 oxycodone prescriptions filled over a three-year period without the red flags being resolved, including:

• Patient Tr.H.: oxycodone, 100 tablets at 30 mg, 10 mg and 15 mg, on multiple occasions between June 2024 and February 2025.
• Patient A.Lo.: oxycodone, 100 tablets at 30 mg, 10 mg and 15 mg, between May 2024 and February 2025.
• Patient Ti.H.: partially filled oxycodone, 110 tablets prescribed and 100 dispensed, between May 2024 and February 2025.
• Patient W.G.: partially filled oxycodone, 104 tablets prescribed and 100 dispensed, between January 2024 and February 2025.
• Patient E.B.: partially filled oxycodone, 108 tablets prescribed and 100 dispensed, between January 2024 and February 2025.
• Patient C.B.: partially filled oxycodone, 105 tablets prescribed and 100 dispensed, between January 2024 and February 2025.

Shared addresses and codeine syrup

The agency also found that between at least May 2 and December 26, 2024, the pharmacy filled multiple prescriptions from the same prescriber for two patients living at the same address in Houston, Texas — hydrocodone/acetaminophen 7.5/325 mg for Patients D.B. and M.F., ranging from 90 to 110 tablets, on at least 16 occasions. On at least six of those occasions, records showed the prescriptions had been issued within 25 minutes of each other.

Separately, DEA found that on at least 30 occasions between October 22, 2024, and April 30, 2025, the pharmacy dispensed 240 milliliters — about eight ounces — or more of promethazine with codeine, a Schedule V narcotic, in quantities far exceeding what a single patient’s cough symptoms would require.

Legal basis and sanction

Weighing the public-interest factors of 21 U.S.C. 823(g)(1), DEA concluded that Factor B, the registrant’s experience in dispensing controlled substances, and Factor D, compliance with applicable law, both weigh in favor of revocation. An independent pharmacy expert retained by the agency concluded that the prescriptions presented red flags highly indicative of abuse and diversion, and that the pharmacy’s practice violated the binding minimum standards governing pharmacy practice in Texas.

Because the registrant accepted no responsibility and offered no evidence to rebut the Government’s case, DEA ordered the revocation and the denial of the pending applications.

The order underscores that DEA treats a pharmacy’s failure to resolve prescription red flags as grounds for losing its registration, and it takes effect November 6, 2026, barring Arenbii Pharmacy LLC from handling controlled substances in Texas.

Source: Federal Register, Vol. 91, No. 193, October 7, 2026, Notices, p. 64170 (official reference: FR Doc. 2026–20533).